LAG-3 Blockade with Relatlimab (BMS-986016) Restores Anti-Leukemic Responses in Chronic Lymphocytic Leukemia.

MLA

Sordo-Bahamonde, Christian, et al. “LAG-3 Blockade with Relatlimab (BMS-986016) Restores Anti-Leukemic Responses in Chronic Lymphocytic Leukemia.” Cancers, vol. 13, no. 9, Apr. 2021. EBSCOhost, https://doi.org/10.3390/cancers13092112.

APA

Sordo-Bahamonde, C., Lorenzo-Herrero, S., González-Rodríguez, A. P., Payer, Á. R., González-García, E., López-Soto, A., & Gonzalez, S. (2021). LAG-3 Blockade with Relatlimab (BMS-986016) Restores Anti-Leukemic Responses in Chronic Lymphocytic Leukemia. Cancers, 13(9). https://doi.org/10.3390/cancers13092112

Chicago

Sordo-Bahamonde, Christian, Seila Lorenzo-Herrero, Ana P González-Rodríguez, Ángel R Payer, Esther González-García, Alejandro López-Soto, and Segundo Gonzalez. 2021. “LAG-3 Blockade with Relatlimab (BMS-986016) Restores Anti-Leukemic Responses in Chronic Lymphocytic Leukemia.” Cancers 13 (9). doi:10.3390/cancers13092112.